Eclipsebio is the exclusive license holder to patents covering key aspects of Ribo-Seq technology developed by inventors Weismann and Ingolia at the University of California, San Fransisco (UCSF)
SAN DIEGO, July 27, 2023 /PRNewswire/ -- Eclipsebio, a leading provider of innovative RNA analysis solutions, announces the launch of its proprietary eRibo Pro™ service, an all-inclusive offering to identify differential transcription and translation as well as ribosome positioning. The launch of eRibo Pro™ marks an important milestone in Eclipsebio's mission to accelerate the development of tomorrow’s key RNA genomics discoveries & medicines by providing researchers with tools to interrogate the complexity of RNA. Eclipsebio will unveil eRibo Pro™ at Hanson Wade’s 3rd mRNA-Based Therapeutics Summit, July 27th, 2023.
eRibo Pro™ is a service solution that streamlines ribosome profiling data collection, allowing researchers to offload sample processing, sequencing, and data analysis. The comprehensive service includes high resolution mapping of ribosome footprints and identification of differentially transcribed and translated genes with interactive reports that allow researchers to make data driven insights.
“The eRibo Pro service significantly accelerates development timelines and offers researchers a hassle-free experience by eliminating the need for extensive staff training and capital equipment.” said Eclipsebio CEO & co-founder Peter Chu, Ph.D. “With cost-effective pricing, eRibo Pro delivers exceptional value, making it an ideal choice for both small-scale studies and large-scale projects, providing researchers with unparalleled access to translation data.”
eRibo Pro™ incorporates exclusively licensed technology for Ribo-Seq developed by Drs. Jonathan Weissman and Nicholas Ingolia at UCSF. The underlying patents cover innovations related to methods for monitoring translation via ribosome profiling, covered under U.S. Patent Numbers 8,486,865, 9,284,547 and 9,677,068.
About Eclipsebio
Eclipsebio is a private biotechnology company headquartered in San Diego, developing first-in-class technologies to accelerate the development of tomorrow’s key RNA genomics discoveries and medicines. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. For more info, visit www.eclipsebio.com.
Contact
Media inquiries can be made to press@eclipsebio.com
Latest news
2026 mRNA Innovators Award Call for Applications
The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics
Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]
Eclipsebio Launches eVERSE™, a First-of-Its-Kind Comprehensive Portfolio of RNA-Focused Datasets for AI Model Success
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE™ portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design.
2025 Data Catalyst Award Announcement
To support researchers as they generate RNA datasets, Eclipsebio is proud to announce the 2025 Data Catalyst Award. Winners of the award will obtain matching funds to cover the cost of generating their control datasets.